Patients with autism spectrum disorders display reproducible functional connectivity alterations

  • Štefan Holiga
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Joerg F. Hipp
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Christopher H. Chatham
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Pilar Garces
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Will Spooren
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Xavier Liogier D’Ardhuy
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Alessandro Bertolino
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Céline Bouquet
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Jan K. Buitelaar
    Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands.
  • Carsten Bours
    Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands.
  • Annika Rausch
    Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands.
  • Marianne Oldehinkel
    Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands.
  • Manuel Bouvard
    Pôle Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital Charles Perrens Bordeaux, 33076 Bordeaux, France.
  • Anouck Amestoy
    Pôle Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital Charles Perrens Bordeaux, 33076 Bordeaux, France.
  • Mireille Caralp
    INSERM, National Biobank Infrastructure, 75013 Paris, France.
  • Sonia Gueguen
    INSERM, Clinical Research Department, 75014 Paris, France.
  • Myriam Ly-Le Moal
    Institut Roche, 92100 Boulogne-Billancourt, France.
  • Josselin Houenou
    Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France.
  • Christian F. Beckmann
    Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands.
  • Eva Loth
    Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.
  • Declan Murphy
    Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.
  • Tony Charman
    Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.
  • Julian Tillmann
    Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.
  • Charles Laidi
    Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France.
  • Richard Delorme
    APHP, Robert Debré Hospital, Child and Adolescent Psychiatry Department, Paris, France.
  • Anita Beggiato
    APHP, Robert Debré Hospital, Child and Adolescent Psychiatry Department, Paris, France.
  • Alexandru Gaman
    Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France.
  • Isabelle Scheid
    Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France.
  • Marion Leboyer
    Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France.
  • Marc-Antoine d’Albis
    Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France.
  • Jeff Sevigny
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Christian Czech
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Federico Bolognani
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Garry D. Honey
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Juergen Dukart
    Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.

抄録

<jats:p>Functional connectivity alterations are conserved in multiple cohorts of patients with autism spectrum disorder.</jats:p>

収録刊行物

  • Science Translational Medicine

    Science Translational Medicine 11 (481), 9223-, 2019-02-27

    American Association for the Advancement of Science (AAAS)

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ